^
    22h
    A Clinical Study Evaluating the Safety, Tolerability, and Effect on HIV Reservoir of Ibalizumab Combined With Chidamide (a Histone Deacetylase Inhibitor) in People Living With HIV (clinicaltrials.gov)
    P1, N=18, Not yet recruiting, First Affiliated Hospital of Zhejiang University
    New P1 trial
    |
    CD4 (CD4 Molecule)
    |
    Yervoy (ipilimumab) • Epidaza (chidamide)
    6d
    Phase II Study of Chidamide-Dinutuximab Beta-Irinotecan-Temozolomide for Refractory/Relapsed Neuroblastoma in Children (clinicaltrials.gov)
    P2, N=27, Recruiting, Tianjin Medical University Cancer Institute and Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    |
    temozolomide • irinotecan • Epidaza (chidamide) • Qarziba (dinutuximab beta)
    9d
    Chidamide Monotherapy for Intermediate-to-High-Risk Myelodysplastic Syndromes (clinicaltrials.gov)
    P2, N=15, Not yet recruiting, Zhongshan Hospital (Xiamen), Fudan University
    New P2 trial
    |
    Epidaza (chidamide)
    12d
    MA-BC-II-047: Exploration of Dalpiciclib + Chidamide in HR+/HER2- Advanced Breast Cancer After Failure of CDK4/6 Inhibitor: a Phase Ⅰb Study (clinicaltrials.gov)
    P1, N=22, Completed, Beijing 302 Hospital | Trial completion date: Nov 2025 --> Mar 2026 | Trial primary completion date: Nov 2024 --> Dec 2025 | Not yet recruiting --> Completed
    Trial completion • Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    Epidaza (chidamide) • AiRuiKang (dalpiciclib)
    12d
    Sequential CDK4/6 inhibition in bone-only metastatic HR+/HER2- breast cancer: a case of prolonged disease control with abemaciclib after clinical progression on palbociclib-based therapy. (PubMed, Front Med (Lausanne))
    A 59-year-old woman with stage IIIA HR+/HER2- breast cancer underwent modified radical mastectomy in 2016, followed by adjuvant AC-P (doxorubicin hydrochloride 70 mg, cyclophosphamide 800 mg, and paclitaxel liposomes 180 mg) chemotherapy, radiotherapy, and letrozole maintenance...Since palbociclib was not yet covered by insurance, she received an initial chidamide + exemestane therapy, which proved ineffective. Using second-line palbociclib combined with fulvestrant and zoledronic acid therapy, disease stabilization was achieved for up to 12 months...As of September 2023, the patient has remained progression-free for >20 months and experienced only manageable grade 2 diarrhea. This case suggests that sequential CDK4/6 inhibition could help achieve >20 months of progression-free disease control in a patient with bone-only HR+/HER2- MBC after clinical progression during prior palbociclib-based therapy and underscored the need for biomarker-guided strategies in this distinct population.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative
    |
    Ibrance (palbociclib) • paclitaxel • doxorubicin hydrochloride • Verzenio (abemaciclib) • cyclophosphamide • fulvestrant • letrozole • Epidaza (chidamide) • exemestane • zoledronic acid
    12d
    Deubiquitinases in lung cancer: Oncogenic mechanisms, metabolic reprogramming, immune evasion, and therapeutic targeting. (PubMed, Pathol Res Pract)
    In LSCC, USP28 stabilizes c-MYC, ΔNp63, and SREBP2; in LUAD, USP22 emerges as an integrative node coupling proliferation, EZH2-mediated MHC-I silencing, PD-L1 stabilization, and ferroptosis resistance; and in SCLC, USP1 mediates NK-cell evasion and MAST1-dependent cisplatin resistance, whereas USP13 sustains FASN-dependent cancer stem cell states. Therapeutic strategies are evolving from small-molecule inhibitors (GNE-6776, AZ1, and SJB2-043) to OTUB1-recruiting deubiquitinase-targeting chimeras (DUBTACs), DCAF-based PROTACs, and repurposed agents (rolapitant, ixazomib, and chidamide). Most evidence remains preclinical; substrate redundancy, validated biomarkers, and selectivity challenges must be addressed before DUB-directed strategies can be translated into biomarker-stratified combination therapies.
    Review • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • VTCN1 (V-Set Domain Containing T Cell Activation Inhibitor 1) • FASN (Fatty acid synthase) • USP22 (Ubiquitin Specific Peptidase 22) • OTUB1 (OTU Deubiquitinase, Ubiquitin Aldehyde Binding 1) • USP1 (Ubiquitin Specific Peptidase 1) • USP13 (Ubiquitin Specific Peptidase 13) • USP25 (Ubiquitin Specific Peptidase 25) • USP7 (Ubiquitin Specific Peptidase 7)
    |
    KRAS mutation
    |
    cisplatin • Ninlaro (ixazomib) • Epidaza (chidamide)
    19d
    Lisaftoclax Plus Chidamide and Rituximab in Relapsed or Refractory Diffuse Large B-cell Lymphoma (clinicaltrials.gov)
    P1/2, N=51, Not yet recruiting, Sun Yat-sen University
    New P1/2 trial
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    Rituxan (rituximab) • Epidaza (chidamide) • lisaftoclax (APG-2575)
    21d
    An Open-label, Single-arm, Multicenter Phase II Clinical Study of Azacitidine, Chidamide Combined With PD-1 Monoclonal Antibody in the Treatment of Refractory/Relapsed Peripheral T-cell Lymphoma. (clinicaltrials.gov)
    P1, N=30, Recruiting, Second Affiliated Hospital of Soochow University
    New P1 trial
    |
    ALK (Anaplastic lymphoma kinase)
    |
    ALK positive • ALK negative
    |
    azacitidine • Epidaza (chidamide)
    30d
    A Safety and Efficacy Trial of Chidamide Combined With NKG2D CAR-NK Cell Therapy for Reducing the HIV Viral Reservoir (clinicaltrials.gov)
    P1/2, N=20, Not yet recruiting, First Affiliated Hospital of Zhejiang University
    New P1/2 trial • First-in-human
    |
    CD4 (CD4 Molecule)
    |
    Epidaza (chidamide)
    1m
    A Multicenter RCT of "3+7" vs Venetoclax + CACAG in Newly Diagnosed Mid/High-Risk AML Patients (clinicaltrials.gov)
    P2, N=160, Recruiting, Chinese PLA General Hospital | Active, not recruiting --> Recruiting
    Enrollment open
    |
    Venclexta (venetoclax) • cytarabine • azacitidine • Epidaza (chidamide) • aclarubicin
    1m
    Chidamide Combined With Chemotherapy and Immunotherapy as First-line Treatment for Advanced Intrahepatic Cholangiocarcinoma (clinicaltrials.gov)
    P2, N=35, Recruiting, Shanghai Zhongshan Hospital
    New P2 trial • IO biomarker
    |
    cisplatin • gemcitabine • Epidaza (chidamide)
    1m
    Synergistic antitumor effect between Olaparib and Chidamide by regulation of MYBL2 in lung cancer. (PubMed, Anticancer Drugs)
    On the other hand, MYBL2 may regulate the expression of cycle protein dependent kinase 1, causing G2M cell cycle arrest. Consequently, the combination of Olaparib and Chidamide synergistically induces cell apoptosis through synthetic lethality and cell cycle arrest to exert an antitumor effect.
    Journal • BRCA Biomarker • PARP Biomarker
    |
    BRCA1 (Breast cancer 1, early onset) • MYBL2 (MYB Proto-Oncogene Like 2)
    |
    Lynparza (olaparib) • Epidaza (chidamide)